Replimune Group, Inc (REPL)

Etorro trading 970x250
Replimune Group, Inc (REPL) Logo

About Replimune Group, Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Address: 500 Unicorn Park, Woburn, MA, United States, 01801

Replimune Group, Inc News and around…

Latest news about Replimune Group, Inc (REPL) common stock and company :

Replimune Appoints Christy Oliger to its Board of Directors
02 Dec, 2021 Yahoo! Finance

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors effective December 1, 2021. “We are delighted to welcome Christy to Replimune’s Board of Directors,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Christy brings nearly 30 years of comm

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
19 Nov, 2021 FinancialContent

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:EQT) from Equal-Weight to Overweight. For the ...

Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
12 Nov, 2021 Yahoo! Finance

RP2 data demonstrates deep and durable responses in difficult to treat cancers both as monotherapy and in combination with Opdivo® (nivolumab) Initiated Phase 1 expansion of RP2 in combination with Opdivo focused on patients with liver metastases WOBURN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced updated interim data from the Phase 1 data fr

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
08 Nov, 2021 FinancialContent

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good ...

Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
01 Oct, 2021 Yahoo! Finance

WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021. Details of Replimune’s poster presentations: Abstract Title: A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-

How The Pieces Add Up: PTH Targets $199
23 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $198.92 per unit.

10 Biggest Price Target Changes For Monday
23 Aug, 2021 FinancialContent

Telsey Advisory Group boosted the price target for Burlington Stores, Inc. (NYSE: BURL) from $380 to $400. Burlington fell 0.4% to ...

We're Not Worried About Replimune Group's (NASDAQ:REPL) Cash Burn
09 Aug, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
06 Aug, 2021 FinancialContent
Replimune to Present at Two Upcoming Investor Conferences
02 Aug, 2021 FinancialContent
Replimune Group Getting Closer To Key Technical Benchmark
12 Jul, 2021 FinancialContent

A Relative Strength Rating upgrade for Replimune Group shows improving technical performance. Will it continue?

Replimune to Present at the William Blair Biotech Focus Conference 2021
07 Jul, 2021 FinancialContent
REPL Makes Bullish Cross Above Critical Moving Average
24 Jun, 2021 FinancialContent

In trading on Thursday, shares of Replimune Group Inc (REPL) crossed above their 200 day moving average of $36.55, changing hands as high as $37.80 per share. Replimune Group Inc shares are currently trading up about 3.7% on the day..

55 Biggest Movers From Yesterday
04 Jun, 2021 FinancialContent

Gainers DLocal Limited (NASDAQ: DLO) shares jumped 54.2% to close at $32.39 on Thursday. DLocal raised around $92.6 million from ...

12 Health Care Stocks Moving In Thursday's Intraday Session
03 Jun, 2021 FinancialContent

Gainers Kindred Biosciences (NASDAQ:KIN) shares increased by 24.08% to $6.75 during Thursday's regular session. ...

46 Stocks Moving In Thursday's Mid-Day Session
03 Jun, 2021 FinancialContent

Gainers GTT Communications, Inc. (NYSE: GTT) shares jumped 66% to $4.16 on abnormally-high volume. The company’s stock also ...

The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
03 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1
03 Jun, 2021 FinancialContent
REPL Makes Notable Cross Below Critical Moving Average
02 Jun, 2021 FinancialContent

In trading on Wednesday, shares of Replimune Group Inc (REPL) crossed below their 200 day moving average of $35.75, changing hands as low as $35.69 per share. Replimune Group Inc shares are currently trading off about 3.6% on the day..

Replimune Group Gets Relative Strength Rating Upgrade
27 May, 2021 FinancialContent

A Relative Strength Rating upgrade for Replimune Group shows improving technical performance. Will it continue?

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
20 May, 2021 FinancialContent
Replimune Appoints Tanya Lewis as Chief Development Operations Officer
10 May, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Intraday Session
05 May, 2021 FinancialContent

Gainers Chiasma (NASDAQ:CHMA) shares moved upwards by 41.9% to $4.03 during Wednesday's regular session. ...

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination
05 May, 2021 FinancialContent
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma
05 May, 2021 Yahoo! Finance

WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with Libtayo® (cemiplimab) versus Libtayo for the treatment of cutaneous squamous cell carcinoma (CSCC), and for IGNYTE, its registration-directed single arm clinical trial in combination with Opdivo® (nivolumab) for the treatment of anti-PD1 failed melanoma. CERPASS “Based on the depth and durability of responses and the manageable safety profile we have seen in patients with non-melanoma skin cancers treated with RP1 in combination with Opdivo to date, we are amending the clinical trial protocol for our Phase 2 CERPASS clinical trial to include complete response (CR) rate as a primary endpoint in addition to overall response rate (ORR), and to reduce target enrollment to 180 patients,” said Robert Coffin, Ph.D., President and Chief Research and Development Officer of Replimune. “Incorporating CR as an independent additional primary endpoint should ensure a robust assessment of the clinical meaningfulness of adding RP1 to Libtayo in the primary data analysis upon which a BLA submission and FDA’s assessment for approval will be based.” Under the modified clinical trial protocol for CERPASS, Replimune plans to add CR rate as an additional independent primary endpoint, in addition to ORR, and to reduce target enrollment from 240 patients to 180 patients. Secondary endpoints will continue to include duration of response, progression-free survival (PFS), and overall survival (OS). Replimune is maintaining its guidance to expect initial data in 2022. Replimune plans to submit the amended CERPASS clinical trial protocol to the U.S. Food and Drug Administration (FDA) in the first half of the year. Libtayo® is a registered trademark of Regeneron. IGNYTE Replimune recently held a Type B meeting with the FDA to discuss the design of the 125-patient, single-arm cohort in the IGNYTE clinical trial which is currently enrolling patients with anti-PD1 failed cutaneous melanoma, with registrational intent. The FDA expressed that while a randomized controlled trial would always be preferred to support licensure, that in this population if the data generated were sufficiently compelling, then the data could be considered for submission by the FDA under the accelerated approval pathway. The FDA also confirmed that a confirmatory trial would be needed as is required under the accelerated approval pathway. The design of the confirmatory trial is intended to be discussed with the FDA prior to a Biologics License Application (BLA) submission. Dr. Coffin commented: “The discussion with the FDA at the Type B meeting provides clarity on the appropriate regulatory pathway to potential approval for RP1 in combination with Opdivo in anti-PD1 failed melanoma based on the data intended to be generated from our ongoing clinical trial. We look forward to releasing initial data from this study during 2022.” Opdivo® is a registered trademark of Bristol Myers Squibb. About CERPASSCERPASS is Replimune’s registration-directed randomized, global Phase 2 clinical study to compare the effects of Libtayo alone versus a combination of Libtayo and Replimune’s investigational oncolytic immunotherapy RP1. The clinical trial will enroll 180 patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) who are naïve to anti-PD1 therapy. The trial will evaluate complete response (CR) rate and objective response rate (ORR) as its two primary efficacy endpoints as assessed by independent review, as well as duration of response, progression-free survival (PFS), and overall survival (OS) as its secondary endpoints. The study is being run under a clinical trial collaboration agreement with Regeneron in which the costs of the trial are shared and full commercial rights retained by Replimune. Libtayo is being jointly developed by Regeneron and Sanofi. About IGNYTEIGNYTE is Replimune’s multi-cohort Phase 1/2 trial of RP1 plus Opdivo®. There are 4 tumor specific cohorts currently enrolling in this trial including a 125-patient extension cohort of RP1 combined with Opdivo in anti-PD-1 failed cutaneous melanoma. This cohort was initiated after completing enrollment in a prior Phase 2 cohort in the same trial of approximately 30 patients with melanoma. The additional thirty patient cohorts are studying RP1 in combination with Opdivo in non-melanoma skin cancers which includes both naïve and anti-PD-1 failed CSCC, in microsatellite instability high, or MSI-H/dMMR tumor types and anti-PD-1 failed non-small cell lung cancer, or NSCLC. This trial is being done under a collaboration and supply agreement with Bristol Myer Squibb. About RP1RP1 is Replimune’s lead Immulytic® product candidate and is based on a proprietary new strain of herpes simplex virus engineered to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response through the expression of a GALV-GP R- fusogenic protein and GM-CSF. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’s Immulytic® platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For more information, please visit www.replimune.com. Forward Looking StatementsThis press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about the design and advancement of our clinical trials, the sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, the potential impact of COVID-19 on our operations and milestones, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. Investor Inquiries Chris BrinzeyWestwicke, an ICR Company339.970.2843chris.brinzey@westwicke.com Media InquiriesLissette SteeleVerge Scientific Communications202.431.4116lsteele@vergescientific.com

Replimune to Host Virtual Investor Event on June 3, 2021
28 Apr, 2021 FinancialContent

Event to begin at 8:00 AM ET

Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
21 Apr, 2021 FinancialContent
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting
12 Apr, 2021 FinancialContent
3 Biotech Stocks That Could Double In 12 Months
17 Mar, 2021 FinancialContent

Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by ...

Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
11 Mar, 2021 FinancialContent

Replimune Group, Inc (REPL) is a NASDAQ Common Stock listed in , ,

970x250